<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:d="http://xbrl.dcca.dk/sob" xmlns:b="http://xbrl.dcca.dk/entryBalanceSheetAccountFormIncomeStatementByNature" xmlns:g="http://xbrl.dcca.dk/mrv" xmlns:f="http://xbrl.dcca.dk/arr" xmlns:e="http://xbrl.dcca.dk/cmn" xmlns:h="http://xbrl.dcca.dk/fsa" xmlns:c="http://xbrl.dcca.dk/gsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://xbrl.dcca.dk/entryBalanceSheetAccountFormIncomeStatementByNature http://archprod.service.eogs.dk/taxonomy/20241001/entryDanishGAAPBalanceSheetAccountFormIncomeStatementByNatureIncludingManagementsReviewStatisticsAndTax20241001.xsd"><link:schemaRef xlink:type="simple" xlink:href="http://archprod.service.eogs.dk/taxonomy/20241001/entryDanishGAAPBalanceSheetAccountFormIncomeStatementByNatureIncludingManagementsReviewStatisticsAndTax20241001.xsd"/><c:ReportingPeriodNumber contextRef="c11" unitRef="u4" decimals="INF">1</c:ReportingPeriodNumber><d:IdentificationOfApprovedAnnualReport contextRef="c11" xml:lang="en">The supervisory board and executive board have today discussed and approved the annual report of OmicVision Biosciences ApS for the financial year 1 September 2023 - 31 December 2024.</d:IdentificationOfApprovedAnnualReport><d:ConfirmationThatAnnualReportIsPresentedInAccordanceWithRequirementsProvidedForByLegislationAnyStandardsAndRequirementsProvidedByArticlesOfAssociationOrByAgreement contextRef="c11" xml:lang="en">The annual report is prepared in accordance with the Danish Financial Statements Act.</d:ConfirmationThatAnnualReportIsPresentedInAccordanceWithRequirementsProvidedForByLegislationAnyStandardsAndRequirementsProvidedByArticlesOfAssociationOrByAgreement><d:ConfirmationThatFinancialStatementGivesTrueAndFairViewOfAssetsLiabilitiesEquityFinancialPositionAndResults contextRef="c11" xml:lang="en">In our opinion, the financial statements give a true and fair view of the company's financial position at 31 December 2024 and of the results of the company's operations for the financial year 1 September 2023 - 31 December 2024.</d:ConfirmationThatFinancialStatementGivesTrueAndFairViewOfAssetsLiabilitiesEquityFinancialPositionAndResults><d:ManagementsStatementAboutManagementsReview contextRef="c11" xml:lang="en">In our opinion, management's review includes a fair review of the matters dealt with in the management's review.</d:ManagementsStatementAboutManagementsReview><d:RecommendationForApprovalOfAnnualReportByGeneralMeeting contextRef="c11" xml:lang="en">Management recommends that the annual report should be approved by the company in general meeting.</d:RecommendationForApprovalOfAnnualReportByGeneralMeeting><e:NameAndSurnameOfMemberOfExecutiveBoard contextRef="c78">Ishani Tara Ummat</e:NameAndSurnameOfMemberOfExecutiveBoard><e:TitleOfMemberOfExecutiveBoard contextRef="c78">CEO</e:TitleOfMemberOfExecutiveBoard><e:NameAndSurnameOfMemberOfExecutiveBoard contextRef="c79">Andreas Mund</e:NameAndSurnameOfMemberOfExecutiveBoard><e:TitleOfMemberOfExecutiveBoard contextRef="c79">director</e:TitleOfMemberOfExecutiveBoard><e:NameAndSurnameOfMemberOfExecutiveBoard contextRef="c80">Maximilian Thomas Dr Strauss</e:NameAndSurnameOfMemberOfExecutiveBoard><e:TitleOfMemberOfExecutiveBoard contextRef="c80">director</e:TitleOfMemberOfExecutiveBoard><e:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="c63">Ole Vorm</e:NameAndSurnameOfMemberOfSupervisoryBoard><e:TitleOfMemberOfSupervisoryBoard contextRef="c63">chairman</e:TitleOfMemberOfSupervisoryBoard><e:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="c64">Andreas Mund</e:NameAndSurnameOfMemberOfSupervisoryBoard><e:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="c65">Maximilian Thomas Dr Strauss</e:NameAndSurnameOfMemberOfSupervisoryBoard><f:AddresseeOfAuditorsReportOnExtendedReviewOfFinancialStatements contextRef="c11" xml:lang="en">To the shareholders of OmicVision Biosciences ApS</f:AddresseeOfAuditorsReportOnExtendedReviewOfFinancialStatements><f:TypeOfModifiedOpinionOnAuditedFinancialStatementsExtendedReview contextRef="c11" xml:lang="en">Opinion</f:TypeOfModifiedOpinionOnAuditedFinancialStatementsExtendedReview><f:OpinionOnFinancialStatementsExtendedReview contextRef="c11" xml:lang="en">We have performed extended review of the financial statements of OmicVision Biosciences ApS for the financial year 1 September 2023 - 31 December 2024, which comprise income statement, balance sheet, statement of changes in equity and notes, including summary of significant accounting policies. The financial statements are prepared under the Danish Financial Statements Act.
Based on the performed work it is our opinion, that the financial statements give a true and fair view of the company's financial position at 31 December 2024 and of the results of the company's operations for the financial year 1 September 2023 - 31 December 2024 in accordance with the Danish Financial Statements Act.</f:OpinionOnFinancialStatementsExtendedReview><f:TypeOfBasisForModifiedOpinionOnFinancialStatementsExtendedReview contextRef="c11" xml:lang="en">Basis for Opinion</f:TypeOfBasisForModifiedOpinionOnFinancialStatementsExtendedReview><f:DescriptionOfQualificationsOfFinancialStatementsExtendedReview contextRef="c11" xml:lang="en">We conducted our extended review in accordance with the Danish Business Authority's standard on auditor's report for small enterprises and FSR - danish auditors' standard on extended review of financial statements in accordance with the Danish Financial Statements Act. Our responsibilities under those standards and requirements are further described in the “Auditor's responsibilities for the extended review of the financial statements” section of our report. We are independent of the company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and IESBA Code. We believe that the evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.</f:DescriptionOfQualificationsOfFinancialStatementsExtendedReview><f:StatementOfExecutiveAndSupervisoryBoardsResponsibilityForFinancialStatementsExtendedReview contextRef="c11" xml:lang="en">Management is responsible for the preparation of financial statements, that give a true and fair view in accordance with the Danish Financial Statements Act and for such internal control as management determines is necessary to enable the preparation of  financial statements that are free from material misstatement, whether due to fraud or error.
In preparing the financial statements, management is responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless management either intends to liquidate the company or to cease operations, or has no realistic alternative but to do so.</f:StatementOfExecutiveAndSupervisoryBoardsResponsibilityForFinancialStatementsExtendedReview><f:StatementOfAuditorsResponsibilityExtendedReview contextRef="c11" xml:lang="en">Our responsibility is to express a conclusion on the accompanying financial statements. This requires us to perform procedures in order to obtain limited assurance for our conclusion on these financial statements, and in addition perform specifically required supplementary procedures in order to obtain additional assurance for our conclusion.
An extended review of financial statements includes procedures primarily consisting of making inquiries of management and others within the entity, as appropriate, applying analytical procedures and the specifically required supplementary procedures, and evaluating the evidence obtained.
The procedures performed in an extended review are less than those performed in an audit and accordingly we do not express an audit opinion on these financial statements.</f:StatementOfAuditorsResponsibilityExtendedReview><f:StatementOnManagementsReviewAuditorsReportOnExtendedReviewFinancialStatementsExtendedReview contextRef="c11" xml:lang="en">Statement on management's review
Management is responsible for management's review.
Our opinion on the financial statements does not cover management's review, and we do not express any form of assurance conclusion thereon.
In connection with our extended review of the financial statements, our responsibility is to read management's review and, in doing so, consider whether management's review is materially inconsistent with the financial statements or our knowledge obtained during the extended review, or otherwise appears to be materially misstated.
Moreover, it is our responsibility to consider whether management's review provides the information required under the Danish Financial Statements Act.
Based on the work we have performed, we conclude that management's review is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statements Act. We did not identify any material misstatement of management's review.</f:StatementOnManagementsReviewAuditorsReportOnExtendedReviewFinancialStatementsExtendedReview><f:ReportingResponsibilitiesAccordingToTheDanishExecutiveOrderOnApprovedAuditorsReportsExtendedReview contextRef="c11" xml:lang="en">Violation of the rules on tax reporting of wages and salaries
The company has, in violation of tax legislation, reported wages and salaries paid to foreign employees to the tax authorities (Skattestyrelsen) incorrectly. Management may be held liable in this respect.
Violation of VAT legislation
The company has, in violation of the VAT law, submitted incorrect VAT declarations to the tax authorities (Skattestyrelsen). Management may be held liable in this respect.</f:ReportingResponsibilitiesAccordingToTheDanishExecutiveOrderOnApprovedAuditorsReportsExtendedReview><f:SignatureOfAuditorsPlace contextRef="c11">Odense</f:SignatureOfAuditorsPlace><f:SignatureOfAuditorsDate contextRef="c11">2025-06-17</f:SignatureOfAuditorsDate><e:NameOfAuditFirm contextRef="c12">Dansk Revision Odense</e:NameOfAuditFirm><e:NameAndSurnameOfAuditor contextRef="c12">Søren Rudolph</e:NameAndSurnameOfAuditor><e:DescriptionOfAuditor contextRef="c12">Partner, State Authorised Public Accountant</e:DescriptionOfAuditor><e:IdentificationNumberOfAuditor contextRef="c12">mne27789</e:IdentificationNumberOfAuditor><g:DescriptionOfPrimaryActivitiesOfEntity contextRef="c11" xml:lang="en">Business review
The company's main activity is to conduct biotechnology research and development of diagnostics for cancer and other diseases, as well as related activities.</g:DescriptionOfPrimaryActivitiesOfEntity><g:DescriptionOfDevelopmentInActivitiesAndFinancialAffairs contextRef="c11" xml:lang="en">Financial review 
The company's income statement for the year ended 31 December 2024 shows a loss of DKK 3.006.677, and the balance sheet at 31 December 2024 shows equity of DKK 4.533.323.</g:DescriptionOfDevelopmentInActivitiesAndFinancialAffairs><g:DescriptionOfSignificantEventsOccurringAfterEndOfReportingPeriod contextRef="c11" xml:lang="en">Significant events occurring after the end of the financial year
No events have occurred after the balance sheet date which could significantly affect the company's financial position.</g:DescriptionOfSignificantEventsOccurringAfterEndOfReportingPeriod><h:GrossProfitLoss contextRef="c11" unitRef="u3" decimals="0">1537595</h:GrossProfitLoss><h:EmployeeBenefitsExpense contextRef="c11" unitRef="u3" decimals="0">4707967</h:EmployeeBenefitsExpense><h:DepreciationAmortisationExpenseAndImpairmentLossesOfPropertyPlantAndEquipmentAndIntangibleAssetsRecognisedInProfitOrLoss contextRef="c11" unitRef="u3" decimals="0">21072</h:DepreciationAmortisationExpenseAndImpairmentLossesOfPropertyPlantAndEquipmentAndIntangibleAssetsRecognisedInProfitOrLoss><h:OtherOperatingExpenses contextRef="c11" unitRef="u3" decimals="0">352753</h:OtherOperatingExpenses><h:ProfitLossFromOrdinaryOperatingActivities contextRef="c11" unitRef="u3" decimals="0">-3544197</h:ProfitLossFromOrdinaryOperatingActivities><h:OtherFinanceIncome contextRef="c11" unitRef="u3" decimals="0">118289</h:OtherFinanceIncome><h:OtherFinanceExpenses contextRef="c11" unitRef="u3" decimals="0">5060</h:OtherFinanceExpenses><h:ProfitLossFromOrdinaryActivitiesBeforeTax contextRef="c11" unitRef="u3" decimals="0">-3430968</h:ProfitLossFromOrdinaryActivitiesBeforeTax><h:TaxExpense contextRef="c11" unitRef="u3" decimals="0">-424291</h:TaxExpense><h:ProfitLoss contextRef="c11" unitRef="u3" decimals="0">-3006677</h:ProfitLoss><h:TransferredToFromRetainedEarnings contextRef="c11" unitRef="u3" decimals="0">-3006677</h:TransferredToFromRetainedEarnings><h:FixturesFittingsToolsAndEquipment contextRef="c49" unitRef="u3" decimals="0">131523</h:FixturesFittingsToolsAndEquipment><h:PropertyPlantAndEquipment contextRef="c49" unitRef="u3" decimals="0">131523</h:PropertyPlantAndEquipment><h:DepositsLongtermInvestmentsAndReceivables contextRef="c49" unitRef="u3" decimals="0">113000</h:DepositsLongtermInvestmentsAndReceivables><h:LongtermInvestmentsAndReceivables contextRef="c49" unitRef="u3" decimals="0">113000</h:LongtermInvestmentsAndReceivables><h:NoncurrentAssets contextRef="c49" unitRef="u3" decimals="0">244523</h:NoncurrentAssets><h:ShorttermTradeReceivables contextRef="c49" unitRef="u3" decimals="0">4020324</h:ShorttermTradeReceivables><h:OtherShorttermReceivables contextRef="c49" unitRef="u3" decimals="0">615931</h:OtherShorttermReceivables><h:ShorttermReceivables contextRef="c49" unitRef="u3" decimals="0">4636255</h:ShorttermReceivables><h:CashAndCashEquivalents contextRef="c49" unitRef="u3" decimals="0">605132</h:CashAndCashEquivalents><h:CurrentAssets contextRef="c49" unitRef="u3" decimals="0">5241387</h:CurrentAssets><h:Assets contextRef="c49" unitRef="u3" decimals="0">5485910</h:Assets><h:ContributedCapital contextRef="c49" unitRef="u3" decimals="0">50000</h:ContributedCapital><h:RetainedEarnings contextRef="c49" unitRef="u3" decimals="0">4483323</h:RetainedEarnings><h:Equity contextRef="c49" unitRef="u3" decimals="0">4533323</h:Equity><h:ShorttermTradePayables contextRef="c49" unitRef="u3" decimals="0">540605</h:ShorttermTradePayables><h:OtherPayablesIncludingTaxPayablesLiabilitiesOtherThanProvisionsShortterm contextRef="c49" unitRef="u3" decimals="0">411982</h:OtherPayablesIncludingTaxPayablesLiabilitiesOtherThanProvisionsShortterm><h:ShorttermLiabilitiesOtherThanProvisions contextRef="c49" unitRef="u3" decimals="0">952587</h:ShorttermLiabilitiesOtherThanProvisions><h:LiabilitiesOtherThanProvisions contextRef="c49" unitRef="u3" decimals="0">952587</h:LiabilitiesOtherThanProvisions><h:LiabilitiesAndEquity contextRef="c49" unitRef="u3" decimals="0">5485910</h:LiabilitiesAndEquity><h:Equity contextRef="c87" unitRef="u3" decimals="0">0</h:Equity><h:Equity contextRef="c105" unitRef="u3" decimals="0">0</h:Equity><h:IncreaseOfCapital contextRef="c88" unitRef="u3" decimals="0">10000</h:IncreaseOfCapital><h:IncreaseOfCapital contextRef="c106" unitRef="u3" decimals="0">7490000</h:IncreaseOfCapital><h:ProfitLoss contextRef="c106" unitRef="u3" decimals="0">-3006677</h:ProfitLoss><h:CashPaymentsConcerningFormationOfEntity contextRef="c88" unitRef="u3" decimals="0">40000</h:CashPaymentsConcerningFormationOfEntity><h:CashPaymentsConcerningFormationOfEntity contextRef="c106" unitRef="u3" decimals="0">0</h:CashPaymentsConcerningFormationOfEntity><h:Equity contextRef="c89" unitRef="u3" decimals="0">50000</h:Equity><h:Equity contextRef="c107" unitRef="u3" decimals="0">4483323</h:Equity><h:InformationOnReportingClassOfEntity contextRef="c11" xml:lang="en">The annual report of OmicVision Biosciences ApS for 2023/24 has been prepared in accordance with the provisions of the Danish Financial Statements Act applying to enterprises of reporting class B, as well as provisions applying to reporting class C entities.
The annual report for 2023/24 is presented in DKK
As 2023/24 is the company's first reporting period, no comparatives have been presented.</h:InformationOnReportingClassOfEntity><h:DescriptionOfGeneralMattersRelatedToRecognitionMeasurementAndChangesInAccountingPolicies contextRef="c11" xml:lang="en">Income is recognised in the income statement as earned, including value adjustments of financial assets and liabilities. All expenses, including amortisation, depreciation and impairment losses, are also recognised in the income statement.
Assets are recognised in the balance sheet when it is probable that future economic benefits will flow to the company and the value of the asset can be measured reliably.
Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow from the company and the value of the liability can be measured reliably.
On initial recognition, assets and liabilities are measured at cost. On subsequent recognition, assets and liabilities are measured as described below for each individual accounting item.
Certain financial assets and liabilities are measured at amortised cost using the effective interest method. Amortised cost is calculated as the historic cost less any installments and plus/less the accumulated amortisation of the difference between the cost and the nominal amount.
On recognition and measurement, allowance is made for predictable losses and risks which occur before the annual report is presented and which confirm or invalidate matters existing at the balance sheet date.</h:DescriptionOfGeneralMattersRelatedToRecognitionMeasurementAndChangesInAccountingPolicies><h:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfGrossProfitLoss contextRef="c11" xml:lang="en">In pursuance of section 32 of the Danish Financial Statements Act, the company does not disclose its revenue. 
Gross profit reflects an aggregation of revenue, changes in inventories of finished goods and work in progress and other operating income less costs of raw materials and consumables and other external expenses.</h:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfGrossProfitLoss><h:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfRevenue contextRef="c11" xml:lang="en">Income from services is recognised on a straight-line basis as the services are provided.
Revenue is measured at fair value of the agreed consideration excluding VAT and taxes charged on behalf of third parties. Revenue is net of all types of discounts granted.</h:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfRevenue><h:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfOtherOperatingExpenses contextRef="c11" xml:lang="en">Other operating expenses comprise items of a secondary nature relative to the company's activities, including losses on the sale of intangible assets and items of property, plant and equipment.</h:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfOtherOperatingExpenses><h:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfExternalExpenses contextRef="c11" xml:lang="en">Other external expenses include expenses related to distribution, sale, advertising, administration, premises, bad debts, payments under operating leases, etc.</h:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfExternalExpenses><h:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfEmployeeBenefitExpense contextRef="c11" xml:lang="en">Staff costs include wages and salaries, including compensated absence and pensions, as well as other social security contributions, etc. made to the entity's employees.</h:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfEmployeeBenefitExpense><h:DescriptionOfMethodsOfImpairmentLossesAndDepreciation contextRef="c11" xml:lang="en">Depreciation, amortisation and impairment of intangible assets and property, plant and equipment comprise the year's depreciation, amortisation and impairment of intangible assets and property, plant and equipment.</h:DescriptionOfMethodsOfImpairmentLossesAndDepreciation><h:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfFinanceIncomeAndExpenses contextRef="c11" xml:lang="en">Financial income and expenses are recognised in the income statement at the amounts that relate to the financial year. Net financials include interest income and expenses, financial expenses relating to finance leases, realised and unrealised capital/exchange gains and losses on securities, liabilities and foreign currency transactions, amortisation of financial assets and liabilities and surcharges and allowances under the Danish Tax Prepayment Scheme, etc.</h:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfFinanceIncomeAndExpenses><h:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxExpenses contextRef="c11" xml:lang="en">Tax for the year, which comprises the current tax charge for the year and changes in the deferred tax charge, is recognised in the income statement as regards the portion that relates to the profit/loss for the year and directly in equity as regards the portion that relates to entries directly in equity.</h:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxExpenses><h:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfPropertyPlantAndEquipment contextRef="c11" xml:lang="en">Items of  plant and machinery and fixtures and fittings, tools and equipment are measured at cost less accumulated depreciation and impairment losses.
The depreciable amount is cost less the expected residual value at the end of the useful life.
Cost comprises the purchase price and any costs directly attributable to the acquisition until the date when the asset is available for use. The cost of self-constructed assets comprises direct and indirect costs of materials, components, sub-suppliers and wages.
Straight-line depreciation is provided on the basis of the following estimated useful lives of the assets:
Useful life Residual value
Other fixtures and fittings, tools and equipment 4 years 0 %

The useful life and residual value are re-assessed annually. A change is accounted for as an accounting estimate, and the impact on amortisation/depreciation is recognised going forward.
Gains and losses on the sale of items of property, plant and equipment are calculated as the difference between the selling price, less costs to sell, and the carrying amount at the time of sale.

Gains or losses on the sale of items of property, plant and equipment are recognised in the income statement under other operating income or other operating expenses, respectively.</h:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfPropertyPlantAndEquipment><h:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfInvestments contextRef="c11" xml:lang="en">Deposits are measured at cost.</h:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfInvestments><h:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfReceivables contextRef="c11" xml:lang="en">Receivables are measured at amortised cost.
An impairment loss is recognised if there is objective evidence that a receivable or a group of receivables is impaired. If there is objective evidence that an individual receivable is impaired, an impairment loss for that individual asset is recognised.</h:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfReceivables><h:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfCashAndCashEquivalents contextRef="c11" xml:lang="en">Cash and cash equivalents comprise cash and deposits at banks.</h:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfCashAndCashEquivalents><h:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxPayablesAndDeferredTax contextRef="c11" xml:lang="en">Current tax liabilities and current tax receivables are recognised in the balance sheet as the estimated tax on the taxable income for the year, adjusted for tax on the taxable income for previous years and tax paid on account.
The company and all its Danish group entities are taxed on a joint basis. The current income tax charge is allocated between the jointly taxed entities relative to their taxable income. Tax losses are allocated based on the full absorption method. The jointly taxed entities are eligible for the Danish Tax Prepayment Scheme.
Deferred tax is measured according to the liability method in respect of temporary differences between the carrying amount of assets and liabilities and their tax base, calculated on the basis of the planned use of the asset and settlement of the liability, respectively. Deferred tax is measured at net realisable value.
Deferred tax is measured according to the tax rules and at the tax rates applicable in the respective countries at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax adjustments resulting from changes in tax rates are recognised in the income statement, with the exception of items taken directly to equity.
Deferred tax assets, including the tax base of tax losses allowed for carry forward, are measured at the value to which the asset is expected to be realised, either as a set-off against tax on future income or as a set-off against deferred tax liabilities within the same legal tax entity. Any deferred net tax assets are measured at net realisable value.</h:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxPayablesAndDeferredTax><h:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfLiabilitiesOtherThanProvisions contextRef="c11" xml:lang="en">Liabilities, which include trade payables, payables to group entities and other payables, are measured at amortised cost, which is usually equivalent to nominal value.</h:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfLiabilitiesOtherThanProvisions><h:DescriptionOfMethodsOfForeignCurrencies contextRef="c11" xml:lang="en">On initial recognition, foreign currency transactions are translated applying the exchange rate at the transaction date. Foreign exchange differences arising between the exchange rates at the transaction date and at the date of payment are recognised in the income statement as financial income or financial expenses. If foreign currency instruments are considered cash flow hedges, any unrealised value adjustments are taken directly to a fair value reserve under ‘Equity’.
Receivables and payables and other monetary items denominated in foreign currencies are translated at the exchange rates at the balance sheet date. The difference between the exchange rates at the balance sheet date and the date at which the receivable or payable arose or was recognised in the latest financial statements is recognised in the income statement as financial income or financial expenses. </h:DescriptionOfMethodsOfForeignCurrencies><h:WagesAndSalaries contextRef="c11" unitRef="u3" decimals="0">4650956</h:WagesAndSalaries><h:PostemploymentBenefitExpense contextRef="c11" unitRef="u3" decimals="0">24098</h:PostemploymentBenefitExpense><h:SocialSecurityContributions contextRef="c11" unitRef="u3" decimals="0">32913</h:SocialSecurityContributions><h:EmployeeBenefitsExpense contextRef="c11" unitRef="u3" decimals="0">4707967</h:EmployeeBenefitsExpense><h:AverageNumberOfEmployees contextRef="c11" unitRef="u4" decimals="INF">4</h:AverageNumberOfEmployees><h:RefundInJointAssessment contextRef="c11" unitRef="u3" decimals="0">-424291</h:RefundInJointAssessment><h:PropertyPlantAndEquipmentGross contextRef="c184" unitRef="u3" decimals="0">0</h:PropertyPlantAndEquipmentGross><h:AdditionsToPropertyPlantAndEquipment contextRef="c185" unitRef="u3" decimals="0">152595</h:AdditionsToPropertyPlantAndEquipment><h:PropertyPlantAndEquipmentGross contextRef="c186" unitRef="u3" decimals="0">152595</h:PropertyPlantAndEquipmentGross><h:AccumulatedImpairmentLossesAndDepreciationOfPropertyPlantAndEquipment contextRef="c184" unitRef="u3" decimals="0">0</h:AccumulatedImpairmentLossesAndDepreciationOfPropertyPlantAndEquipment><h:DepreciationOfPropertyPlantAndEquipment contextRef="c185" unitRef="u3" decimals="0">21072</h:DepreciationOfPropertyPlantAndEquipment><h:AccumulatedImpairmentLossesAndDepreciationOfPropertyPlantAndEquipment contextRef="c186" unitRef="u3" decimals="0">-21072</h:AccumulatedImpairmentLossesAndDepreciationOfPropertyPlantAndEquipment><h:PropertyPlantAndEquipment contextRef="c186" unitRef="u3" decimals="0">131523</h:PropertyPlantAndEquipment><h:InvestmentsGross contextRef="c952" unitRef="u3" decimals="0">0</h:InvestmentsGross><h:AdditionsToInvestments contextRef="c953" unitRef="u3" decimals="0">113000</h:AdditionsToInvestments><h:InvestmentsGross contextRef="c954" unitRef="u3" decimals="0">113000</h:InvestmentsGross><h:LongtermInvestmentsAndReceivables contextRef="c954" unitRef="u3" decimals="0">113000</h:LongtermInvestmentsAndReceivables><h:DisclosureOfContingentLiabilities contextRef="c11" xml:lang="en">Recourse and non-recourse guarantee commitments
The company is jointly taxed with its former parent company, VOMA Holding A/S (management company), and jointly and severally liable with other jointly taxed entities for payment of income taxes for income year 2024. The joint taxation was terminated on 30 August 2024.
Other contingent liabilities not recognised in balance sheet
The company has a lease obligation with a 3-month notice period. The lease obligation for 3 months amounts to DKK 339.000.</h:DisclosureOfContingentLiabilities><c:InformationOnTypeOfSubmittedReport contextRef="c11">Årsrapport</c:InformationOnTypeOfSubmittedReport><c:IdentificationNumberCvrOfSubmittingEnterprise contextRef="c11">82218912</c:IdentificationNumberCvrOfSubmittingEnterprise><c:NameOfSubmittingEnterprise contextRef="c11">Dansk Revision Odense</c:NameOfSubmittingEnterprise><c:AddressOfSubmittingEnterpriseStreetAndNumber contextRef="c11">Langelinie 79</c:AddressOfSubmittingEnterpriseStreetAndNumber><c:AddressOfSubmittingEnterprisePostcodeAndTown contextRef="c11">5230 Odense M</c:AddressOfSubmittingEnterprisePostcodeAndTown><c:ReportingPeriodStartDate contextRef="c11">2023-09-01</c:ReportingPeriodStartDate><c:ReportingPeriodEndDate contextRef="c11">2024-12-31</c:ReportingPeriodEndDate><c:IdentificationNumberCvrOfReportingEntity contextRef="c11">44285584</c:IdentificationNumberCvrOfReportingEntity><c:NameOfReportingEntity contextRef="c11">OmicVision Biosciences ApS</c:NameOfReportingEntity><c:AddressOfReportingEntityStreetName contextRef="c11">Ole Maaløes Vej</c:AddressOfReportingEntityStreetName><c:AddressOfReportingEntityStreetBuildingIdentifier contextRef="c11">3, 1.</c:AddressOfReportingEntityStreetBuildingIdentifier><c:AddressOfReportingEntityPostCodeIdentifier contextRef="c11">2200</c:AddressOfReportingEntityPostCodeIdentifier><c:AddressOfReportingEntityDistrictName contextRef="c11">København N</c:AddressOfReportingEntityDistrictName><c:AddressOfReportingEntityCountryIdentificationCode contextRef="c11">DK</c:AddressOfReportingEntityCountryIdentificationCode><c:AddressOfReportingEntityCountry contextRef="c11">Danmark</c:AddressOfReportingEntityCountry><c:DateOfFoundationOfReportingEntity contextRef="c11">2023-09-01</c:DateOfFoundationOfReportingEntity><c:RegisteredOfficeOfReportingEntity contextRef="c11">København</c:RegisteredOfficeOfReportingEntity><e:NameOfAuditFirm contextRef="c12">Dansk Revision Odense</e:NameOfAuditFirm><e:IdentificationNumberCvrOfAuditFirm contextRef="c12">82218912</e:IdentificationNumberCvrOfAuditFirm><e:NameAndSurnameOfAuditor contextRef="c12">Søren Rudolph</e:NameAndSurnameOfAuditor><e:DescriptionOfAuditor contextRef="c12">Partner, State Authorised Public Accountant</e:DescriptionOfAuditor><c:AddressOfAuditorStreetName contextRef="c12">Langelinie</c:AddressOfAuditorStreetName><c:AddressOfAuditorStreetBuildingIdentifier contextRef="c12">79</c:AddressOfAuditorStreetBuildingIdentifier><c:AddressOfAuditorPostCodeIdentifier contextRef="c12">5230</c:AddressOfAuditorPostCodeIdentifier><c:AddressOfAuditorDistrictName contextRef="c12">Odense M</c:AddressOfAuditorDistrictName><c:AddressOfAuditorCountryIdentificationCode contextRef="c12">DK</c:AddressOfAuditorCountryIdentificationCode><c:AddressOfAuditorCountry contextRef="c12">Danmark</c:AddressOfAuditorCountry><c:DateOfGeneralMeeting contextRef="c11">2025-06-17</c:DateOfGeneralMeeting><c:NameAndSurnameOfChairmanOfGeneralMeeting contextRef="c11">Ole Vorm</c:NameAndSurnameOfChairmanOfGeneralMeeting><h:ClassOfReportingEntity contextRef="c11">Regnskabsklasse B</h:ClassOfReportingEntity><h:SelectedElementsFromReportingClassC contextRef="c11">true</h:SelectedElementsFromReportingClassC><e:TypeOfAuditorAssistance contextRef="c11">Erklæring om udvidet gennemgang</e:TypeOfAuditorAssistance><c:ToolForPreparingTheXBRLInstanceDocument contextRef="c11">CaseWare-FSR</c:ToolForPreparingTheXBRLInstanceDocument><f:ReportingResponsibilitiesAccordingToTheDanishExecutiveOrderOnApprovedAuditorsReportsEspeciallyTheCriminalCodeAndFiscalTaxAndSubsidyLegislationExtendedReview contextRef="c11">true</f:ReportingResponsibilitiesAccordingToTheDanishExecutiveOrderOnApprovedAuditorsReportsEspeciallyTheCriminalCodeAndFiscalTaxAndSubsidyLegislationExtendedReview><f:ReportingResponsibilitiesAccordingToTheDanishExecutiveOrderOnApprovedAuditorsReportsEspeciallyTheCompaniesActOrEquivalentLegislationThatTheCompanyIsSubjectToExtendedReview contextRef="c11">false</f:ReportingResponsibilitiesAccordingToTheDanishExecutiveOrderOnApprovedAuditorsReportsEspeciallyTheCompaniesActOrEquivalentLegislationThatTheCompanyIsSubjectToExtendedReview><f:ReportingResponsibilitiesAccordingToTheDanishExecutiveOrderOnApprovedAuditorsReportsEspeciallyLegislationOnFinancialReportingIncludingAccountingAndStorageOfAccountingRecordsExtendedReview contextRef="c11">false</f:ReportingResponsibilitiesAccordingToTheDanishExecutiveOrderOnApprovedAuditorsReportsEspeciallyLegislationOnFinancialReportingIncludingAccountingAndStorageOfAccountingRecordsExtendedReview><f:ReportingResponsibilitiesAccordingToTheDanishExecutiveOrderOnApprovedAuditorsReportsEspeciallyOtherMattersExtendedReview contextRef="c11">false</f:ReportingResponsibilitiesAccordingToTheDanishExecutiveOrderOnApprovedAuditorsReportsEspeciallyOtherMattersExtendedReview><!--Aktuelle periode enkelt selskab--><context id="c11"><entity><identifier scheme="http://www.dcca.dk/cvr">44285584</identifier></entity><period><startDate>2023-09-01</startDate><endDate>2024-12-31</endDate></period></context><!--REVISOR1--><context id="c12"><entity><identifier scheme="http://www.dcca.dk/cvr">44285584</identifier></entity><period><startDate>2023-09-01</startDate><endDate>2024-12-31</endDate></period><scenario><xbrldi:typedMember dimension="e:IdentificationOfAuditorDimension"><e:auditorIdentifier>1</e:auditorIdentifier></xbrldi:typedMember></scenario></context><!--Slutdato aktuelle periode enkelt selskab--><context id="c49"><entity><identifier scheme="http://www.dcca.dk/cvr">44285584</identifier></entity><period><instant>2024-12-31</instant></period></context><!--BOARD1--><context id="c63"><entity><identifier scheme="http://www.dcca.dk/cvr">44285584</identifier></entity><period><startDate>2023-09-01</startDate><endDate>2024-12-31</endDate></period><scenario><xbrldi:typedMember dimension="e:IdentificationOfMemberOfSupervisoryBoardDimension"><e:memberOfBoardIdentifier>1</e:memberOfBoardIdentifier></xbrldi:typedMember></scenario></context><!--BOARD2--><context id="c64"><entity><identifier scheme="http://www.dcca.dk/cvr">44285584</identifier></entity><period><startDate>2023-09-01</startDate><endDate>2024-12-31</endDate></period><scenario><xbrldi:typedMember dimension="e:IdentificationOfMemberOfSupervisoryBoardDimension"><e:memberOfBoardIdentifier>2</e:memberOfBoardIdentifier></xbrldi:typedMember></scenario></context><!--BOARD3--><context id="c65"><entity><identifier scheme="http://www.dcca.dk/cvr">44285584</identifier></entity><period><startDate>2023-09-01</startDate><endDate>2024-12-31</endDate></period><scenario><xbrldi:typedMember dimension="e:IdentificationOfMemberOfSupervisoryBoardDimension"><e:memberOfBoardIdentifier>3</e:memberOfBoardIdentifier></xbrldi:typedMember></scenario></context><!--CEO1--><context id="c78"><entity><identifier scheme="http://www.dcca.dk/cvr">44285584</identifier></entity><period><startDate>2023-09-01</startDate><endDate>2024-12-31</endDate></period><scenario><xbrldi:typedMember dimension="e:IdentificationOfMemberOfExecutiveBoardDimension"><e:memberOfBoardIdentifier>1</e:memberOfBoardIdentifier></xbrldi:typedMember></scenario></context><!--CEO2--><context id="c79"><entity><identifier scheme="http://www.dcca.dk/cvr">44285584</identifier></entity><period><startDate>2023-09-01</startDate><endDate>2024-12-31</endDate></period><scenario><xbrldi:typedMember dimension="e:IdentificationOfMemberOfExecutiveBoardDimension"><e:memberOfBoardIdentifier>2</e:memberOfBoardIdentifier></xbrldi:typedMember></scenario></context><!--CEO3--><context id="c80"><entity><identifier scheme="http://www.dcca.dk/cvr">44285584</identifier></entity><period><startDate>2023-09-01</startDate><endDate>2024-12-31</endDate></period><scenario><xbrldi:typedMember dimension="e:IdentificationOfMemberOfExecutiveBoardDimension"><e:memberOfBoardIdentifier>3</e:memberOfBoardIdentifier></xbrldi:typedMember></scenario></context><!--Virksomhedskapital aktuel primo--><context id="c87"><entity><identifier scheme="http://www.dcca.dk/cvr">44285584</identifier></entity><period><instant>2023-09-01</instant></period><scenario><xbrldi:explicitMember dimension="h:ClassesOfEquityDimension">h:ContributedCapitalMember</xbrldi:explicitMember></scenario></context><!--Virksomhedskapital aktuel i aaret--><context id="c88"><entity><identifier scheme="http://www.dcca.dk/cvr">44285584</identifier></entity><period><startDate>2023-09-01</startDate><endDate>2024-12-31</endDate></period><scenario><xbrldi:explicitMember dimension="h:ClassesOfEquityDimension">h:ContributedCapitalMember</xbrldi:explicitMember></scenario></context><!--Virksomhedskapital aktuel ultimo--><context id="c89"><entity><identifier scheme="http://www.dcca.dk/cvr">44285584</identifier></entity><period><instant>2024-12-31</instant></period><scenario><xbrldi:explicitMember dimension="h:ClassesOfEquityDimension">h:ContributedCapitalMember</xbrldi:explicitMember></scenario></context><!--Overfort res aktuel primo--><context id="c105"><entity><identifier scheme="http://www.dcca.dk/cvr">44285584</identifier></entity><period><instant>2023-09-01</instant></period><scenario><xbrldi:explicitMember dimension="h:ClassesOfEquityDimension">h:RetainedEarningsMember</xbrldi:explicitMember></scenario></context><!--Overfort res aktuel i aaret--><context id="c106"><entity><identifier scheme="http://www.dcca.dk/cvr">44285584</identifier></entity><period><startDate>2023-09-01</startDate><endDate>2024-12-31</endDate></period><scenario><xbrldi:explicitMember dimension="h:ClassesOfEquityDimension">h:RetainedEarningsMember</xbrldi:explicitMember></scenario></context><!--Overfort res aktuel ultimo--><context id="c107"><entity><identifier scheme="http://www.dcca.dk/cvr">44285584</identifier></entity><period><instant>2024-12-31</instant></period><scenario><xbrldi:explicitMember dimension="h:ClassesOfEquityDimension">h:RetainedEarningsMember</xbrldi:explicitMember></scenario></context><!--Andre anlag aktuel primo--><context id="c184"><entity><identifier scheme="http://www.dcca.dk/cvr">44285584</identifier></entity><period><instant>2023-09-01</instant></period><scenario><xbrldi:explicitMember dimension="h:ClassesOfPropertyPlantAndEquipmentDimension">h:FixturesFittingsToolsAndEquipmentMember</xbrldi:explicitMember></scenario></context><!--Andre anlag aktuel i aaret--><context id="c185"><entity><identifier scheme="http://www.dcca.dk/cvr">44285584</identifier></entity><period><startDate>2023-09-01</startDate><endDate>2024-12-31</endDate></period><scenario><xbrldi:explicitMember dimension="h:ClassesOfPropertyPlantAndEquipmentDimension">h:FixturesFittingsToolsAndEquipmentMember</xbrldi:explicitMember></scenario></context><!--Andre anlag aktuel ultimo--><context id="c186"><entity><identifier scheme="http://www.dcca.dk/cvr">44285584</identifier></entity><period><instant>2024-12-31</instant></period><scenario><xbrldi:explicitMember dimension="h:ClassesOfPropertyPlantAndEquipmentDimension">h:FixturesFittingsToolsAndEquipmentMember</xbrldi:explicitMember></scenario></context><!--Deposita aktuel primo--><context id="c952"><entity><identifier scheme="http://www.dcca.dk/cvr">44285584</identifier></entity><period><instant>2023-09-01</instant></period><scenario><xbrldi:explicitMember dimension="h:ClassesOfInvestmentsDimension">h:DepositsLongtermInvestmentsAndReceivablesMember</xbrldi:explicitMember></scenario></context><!--Deposita aktuel i aaret--><context id="c953"><entity><identifier scheme="http://www.dcca.dk/cvr">44285584</identifier></entity><period><startDate>2023-09-01</startDate><endDate>2024-12-31</endDate></period><scenario><xbrldi:explicitMember dimension="h:ClassesOfInvestmentsDimension">h:DepositsLongtermInvestmentsAndReceivablesMember</xbrldi:explicitMember></scenario></context><!--Deposita aktuel ultimo--><context id="c954"><entity><identifier scheme="http://www.dcca.dk/cvr">44285584</identifier></entity><period><instant>2024-12-31</instant></period><scenario><xbrldi:explicitMember dimension="h:ClassesOfInvestmentsDimension">h:DepositsLongtermInvestmentsAndReceivablesMember</xbrldi:explicitMember></scenario></context><!--DKK enere--><unit id="u3"><measure>iso4217:DKK</measure></unit><!--Antal--><unit id="u4"><measure>xbrli:pure</measure></unit></xbrl>












